BACKGROUND: The Veterans Aging Cohort Study (VACS) Index is associated with all-cause mortality in individuals infected with human immunodeficiency virus (HIV). It is also associated with markers of inflammation and may thus reflect physiologic frailty. This analysis explores the association between physiologic frailty, as assessed by the VACS Index, and fragility fracture. METHODS: HIV-infected men from VACS were included. We identified hip, vertebral, and upper arm fractures using ICD-9-CM codes. We used Cox regression models to assess fragility fracture risk factors including the VACS Index, its components (age, hepatitis C status, FIB-4 score, estimated glomerular filtration rate, hemoglobin, HIV RNA, CD4 count), and previously identified risk factors for fragility fractures. RESULTS: We included 40 115 HIV-infected male Veterans. They experienced 588 first fragility fractures over 6.0 ± 3.9 years. The VACS Index score (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.11-1.19), white race (HR, 1.92; 95% CI, 1.63-2.28), body mass index (HR, 0.94; 95% CI, .92-.96), alcohol-related diagnoses (HR, 1.65; 95% CI, 1.26-2.17), cerebrovascular disease (HR, 1.95; 95% CI, 1.14-3.33), proton pump inhibitor use (HR, 1.87; 95% CI, 1.54-2.27), and protease inhibitor use (HR, 1.25; 95% CI, 1.04-1.50) were associated with fracture risk. Components of the VACS Index score most strongly associated with fracture risk were age (HR, 1.40; 95% CI, 1.27-1.54), log HIV RNA (HR, 0.91; 95% CI, .88-.94), and hemoglobin level (HR, 0.82; 95% CI, .78-.86). CONCLUSIONS: Frailty, as measured by the VACS Index, is an important predictor of fragility fractures among HIV-infected male Veterans.
BACKGROUND: The Veterans Aging Cohort Study (VACS) Index is associated with all-cause mortality in individuals infected with human immunodeficiency virus (HIV). It is also associated with markers of inflammation and may thus reflect physiologic frailty. This analysis explores the association between physiologic frailty, as assessed by the VACS Index, and fragility fracture. METHODS:HIV-infectedmen from VACS were included. We identified hip, vertebral, and upper arm fractures using ICD-9-CM codes. We used Cox regression models to assess fragility fracture risk factors including the VACS Index, its components (age, hepatitis C status, FIB-4 score, estimated glomerular filtration rate, hemoglobin, HIV RNA, CD4 count), and previously identified risk factors for fragility fractures. RESULTS: We included 40 115 HIV-infected male Veterans. They experienced 588 first fragility fractures over 6.0 ± 3.9 years. The VACS Index score (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.11-1.19), white race (HR, 1.92; 95% CI, 1.63-2.28), body mass index (HR, 0.94; 95% CI, .92-.96), alcohol-related diagnoses (HR, 1.65; 95% CI, 1.26-2.17), cerebrovascular disease (HR, 1.95; 95% CI, 1.14-3.33), proton pump inhibitor use (HR, 1.87; 95% CI, 1.54-2.27), and protease inhibitor use (HR, 1.25; 95% CI, 1.04-1.50) were associated with fracture risk. Components of the VACS Index score most strongly associated with fracture risk were age (HR, 1.40; 95% CI, 1.27-1.54), log HIV RNA (HR, 0.91; 95% CI, .88-.94), and hemoglobin level (HR, 0.82; 95% CI, .78-.86). CONCLUSIONS: Frailty, as measured by the VACS Index, is an important predictor of fragility fractures among HIV-infected male Veterans.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Krisann K Oursler; Joseph L Goulet; Stephen Crystal; Amy C Justice; Kristina Crothers; Adeel A Butt; Maria C Rodriguez-Barradas; Knachelle Favors; David Leaf; Leslie I Katzel; John D Sorkin Journal: AIDS Patient Care STDS Date: 2011-01 Impact factor: 5.078
Authors: Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Yungtai Lo; Robert S Klein Journal: AIDS Date: 2007-03-12 Impact factor: 4.177
Authors: Peggy M Cawthon; Stephanie L Harrison; Elizabeth Barrett-Connor; Howard A Fink; Jane A Cauley; Cora E Lewis; Eric S Orwoll; Steven R Cummings Journal: J Am Geriatr Soc Date: 2006-11 Impact factor: 5.562
Authors: Michael T Yin; Chiyuan A Zhang; Donald J McMahon; David C Ferris; Dinaz Irani; Ivelisse Colon; Serge Cremers; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: Ricardo M Lima; Lídia M A Bezerra; Heloisa T Rabelo; Maria A F Silva; Antonio J R Silva; Martim Bottaro; Ricardo J de Oliveira Journal: J Clin Densitom Date: 2008-12-11 Impact factor: 2.617
Authors: Christopher T Rentsch; David A Fiellin; Kendall J Bryant; Amy C Justice; Janet P Tate Journal: Alcohol Clin Exp Res Date: 2019-02-03 Impact factor: 3.455
Authors: Michelle A Kendall; Katherine Tassiopoulos; Grace A McComsey; Michael T Yin Journal: AIDS Res Hum Retroviruses Date: 2015-07-16 Impact factor: 2.205
Authors: Jeremy Walston; Thomas N Robinson; Susan Zieman; Frances McFarland; Christopher R Carpenter; Keri N Althoff; Melissa K Andrew; Caroline S Blaum; Patrick J Brown; Brian Buta; E Wesley Ely; Luigi Ferrucci; Kevin P High; Stephen B Kritchevsky; Kenneth Rockwood; Kenneth E Schmader; Felipe Sierra; Kaycee M Sink; Ravi Varadhan; Arti Hurria Journal: J Am Geriatr Soc Date: 2017-04-19 Impact factor: 5.562
Authors: Kathleen M Akgün; Janet P Tate; Kristina Crothers; Stephen Crystal; David A Leaf; Julie Womack; Todd T Brown; Amy C Justice; Krisann K Oursler Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492
Authors: María J Marquine; Jessica L Montoya; Anya Umlauf; Pariya L Fazeli; Ben Gouaux; Robert K Heaton; Ronald J Ellis; Scott L Letendre; Igor Grant; David J Moore Journal: Clin Infect Dis Date: 2016-05-19 Impact factor: 9.079
Authors: M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza Journal: Clin Exp Immunol Date: 2016-08-09 Impact factor: 4.330